Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Afinitor fails Phase III gastric cancer trial

This article was originally published in Scrip

Executive Summary

Novartis's mTOR inhibitor everolimus (marketed as Afinitor) has failed to meet the primary endpoint in a Phase III study in advanced gastric cancer. The company had previously been hoping to file for its approval in this indication this year, having already obtained US and EU approval for its use in kidney cancer and neuroendocrine tumours of pancreatic origin. It had obtained orphan drug status in the gastric indication in both the EU and US last year. Novartis is also hoping to gain FDA and EMA approval of Afinitor in advanced ER+/HER2- breast cancer this year.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts